Clareo Health | An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World Practice
An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World Practice
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of moderate to severe active rheumatoid arthritis (RA) upon judgment of the treating physician.
Upadacitinib prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies and upadacitinib treatment was started within 1 week before the enrollment.
Physician decision on participant treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.
You may not be if
Participants who cannot be treated with upadacitinib as per SmPC or local prescription criteria.
Prior treatment course with upadacitinib or the current upadacitinib treatment was started more than 1 week prior to enrollment.
Participant currently participating in any interventional study.
